General Electric Company (GE) 26.10 $GE
SIFI Status Upsets MetLife; Will This Affect Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:25PM CDT
MetLife Inc. (MET) is in the final leg of being acknowledged as a non-bank systemically important financial institution (SIFI).
5 Contrarian Stock Picks With Strong Growth Outlooks and Share Buybacks
at The Street - Fri Sep 05, 3:33PM CDT
The stock market may be overpriced based on several common measures. But you can still find stocks trading at bargain prices with good prospects for sales and earnings growth.
Cameron International (CAM): Why this Stock is Still a Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:10PM CDT
Cameron International Corp. (CAM) remains well positioned to maintain a strong earnings growth trajectory in the near to medium term.
How to Get a 1,000% Return
at The Street - Fri Sep 05, 3:05PM CDT
As option traders, we all search for that Holy Grail that will explain the right edge of the chart.
Most active New York Stock Exchange-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Middday Glance: Tools and Appliances companies
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 1 p.m.:
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
How Will General Electric (GE) Stock React to Dividend Declaration?
at The Street - Fri Sep 05, 1:37PM CDT
Shares of General Electric (GE) rose in afternoon trading Friday after the company declared its quarterly dividend.
GE Board of Directors Authorizes Regular Quarterly Dividend
Business Wire - Fri Sep 05, 11:36AM CDT
The Board of Directors of GE (NYSE:GE) today declared a $0.22 per share dividend on the outstanding common stock of the Company payable on October 27, 2014, with a record date of September 22, 2014 and an ex-dividend date of September 18, 2014.
Early Glance: Tools and Appliances companies
AP - Fri Sep 05, 9:12AM CDT
NEW YORK (AP) — Shares of some top tools and appliances companies are down at 10 a.m.:
Regulators Place MetLife in 'Systemic' Risk Category
at The Street - Fri Sep 05, 8:26AM CDT
A council of regulators preliminarily designated Metlife as "systemically important," in a categorization that eventually will impose new liquidity and capital restrictions on the mega-insurer.
Global Oligonucleotide Synthesis (Equipment, Reagents & Synthesized Oligonucleotides) Market 2014-2019 - Product & Services, End-User , Application Analysis
M2 - Fri Sep 05, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3xc5t/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. Oligonucleotide synthesis has a vast number of applications in nucleic acid array-based technologies, library preparations, next-generation sequencing methods, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning and genetic engineering, and synthetic biology, among others. Apart from the growing applications of oligos,increasing R&D expenditure in pharmaceutical and biotechnology companies, the evolving significance of RNA-interference oligos in therapeutics and diagnostics, increasing venture capitalist and governmental funding and support, and rapid technological innovations are other factors driving this market's growth. The relatively-untapped Asia-Pacificmarket,and the growth in magnitude of R&D activities in the region,has opened an array of opportunities for players in the oligonucleotide synthesis market. However, regulatory barriers, especially for therapeutic oligos, and downward pricing pressure are the major factors restraining the growth of this market. By products and services, the market is broadly segmented into equipment, reagents, and synthesized oligonucleotides. Among these segments, the synthesized oligonucleotides market segment is expected to register the highest growth rate during the forecast period, owing to the increasing number of applications of synthesized oligonucleotides in research, diagnostics and therapeutics, and a growing demand for custom oligos. The market, by applications, is classified into diagnostics, research, and therapeutics. Research applications are further segmented into PCR, qPCR, sequencing, gene synthesis, and others. The therapeutics market is further segmented into DNA/antisense oligos, RNAi, aptamers, and others. In terms of applications, the research segment commanded the largest share in 2014, while the diagnostics segment is expected to be the fastest-growing segment in the oligonucleotide synthesis market. The therapeutics segment is gaining increasing importance with growing RNAi applications. However, stringent regulatory requirements pose a major challenge for this market. By end users, the market is segmented into academic research institutes, pharmaceutical and biotech firms, and diagnostic labs. Academic research institutes accounted for the largest share of the market in 2014; however, diagnostic laboratories are expected to be the fastest-growing end user segment during the forecast period, owing to growthin the molecular diagnostics field. Scope of the Report By Products & Services - Equipment - Reagents - Synthesized Oligonucleotides By Product Type - Primers - Probes - Intermediate-Scale Synthesis - Large-Scale Synthesis By Service Type - Pre-designed Oligos - Custom Oligos By Application Diagnostics Research - PCR - QPCR - Sequencing - Gene Synthesis - Others Therapeutics - DNA/Antisense Oligos - RNAi Oligos - Aptamer Oligos - Others By End User - Academic Research Institutes - Diagnostic Laboratories - Pharmaceutical & Biotechnology Companies - Others Companies Mentioned - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/c3...nucleotide
Market Maker Surveillance Report. BAC, GE, MRVL, USB, WFC, GCVRZ, Bullishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. BANK OF AMERICA CORPORATION (NYSE:BAC), General Electric Co (NYSE:GE), Marvell Technology Group Ltd (NASDAQ:MRVL), U.S. Bancorp (NYSE:USB), WELLS FARGO & COMPANY (NYSE:WFC), Sanofi SA (NASDAQ:GCVRZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Regulators may put stricter oversight on MetLife
By MARCY GORDON - AP - Thu Sep 04, 6:32PM CDT
WASHINGTON (AP) — U.S. regulators are proposing to label insurer MetLife Inc. as a potential threat to the financial system, a designation that brings stricter government oversight.
GE 3D imaging device OK'd
at Investor's Business Daily - Thu Sep 04, 5:43PM CDT
A 3D breast cancer imaging device developed by General Electric (GE) won FDA approval, the company said. The device is expected to provide a clearer view of carcinomas but produce no more radiation than today's 2D devices. It's also seen increasing...
Final Glance: Tools and Appliances companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top tools and appliances companies were mixed at the close of trading:
GE, Electrolux Deal Could Be Announced Next Week
at Investor's Business Daily - Thu Sep 04, 12:43PM CDT
General Electric (GE) could reach a deal to sell its home appliance business to Electrolux as early as next week, according to a Reuters report Thursday. The conglomerate has been looking to shed underperforming segments to focus on its industrial...
SIFI Status Upsets MetLife; Will This Affect Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:25PM CDT
MetLife Inc. (MET) is in the final leg of being acknowledged as a non-bank systemically important financial institution (SIFI).
5 Contrarian Stock Picks With Strong Growth Outlooks and Share Buybacks
at The Street - Fri Sep 05, 3:33PM CDT
The stock market may be overpriced based on several common measures. But you can still find stocks trading at bargain prices with good prospects for sales and earnings growth.
Cameron International (CAM): Why this Stock is Still a Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:10PM CDT
Cameron International Corp. (CAM) remains well positioned to maintain a strong earnings growth trajectory in the near to medium term.
How to Get a 1,000% Return
at The Street - Fri Sep 05, 3:05PM CDT
As option traders, we all search for that Holy Grail that will explain the right edge of the chart.
Most active New York Stock Exchange-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Middday Glance: Tools and Appliances companies
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 1 p.m.:
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
How Will General Electric (GE) Stock React to Dividend Declaration?
at The Street - Fri Sep 05, 1:37PM CDT
Shares of General Electric (GE) rose in afternoon trading Friday after the company declared its quarterly dividend.
GE Board of Directors Authorizes Regular Quarterly Dividend
Business Wire - Fri Sep 05, 11:36AM CDT
The Board of Directors of GE (NYSE:GE) today declared a $0.22 per share dividend on the outstanding common stock of the Company payable on October 27, 2014, with a record date of September 22, 2014 and an ex-dividend date of September 18, 2014.
Early Glance: Tools and Appliances companies
AP - Fri Sep 05, 9:12AM CDT
NEW YORK (AP) — Shares of some top tools and appliances companies are down at 10 a.m.:
Regulators Place MetLife in 'Systemic' Risk Category
at The Street - Fri Sep 05, 8:26AM CDT
A council of regulators preliminarily designated Metlife as "systemically important," in a categorization that eventually will impose new liquidity and capital restrictions on the mega-insurer.
Global Oligonucleotide Synthesis (Equipment, Reagents & Synthesized Oligonucleotides) Market 2014-2019 - Product & Services, End-User , Application Analysis
M2 - Fri Sep 05, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3xc5t/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. Oligonucleotide synthesis has a vast number of applications in nucleic acid array-based technologies, library preparations, next-generation sequencing methods, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning and genetic engineering, and synthetic biology, among others. Apart from the growing applications of oligos,increasing R&D expenditure in pharmaceutical and biotechnology companies, the evolving significance of RNA-interference oligos in therapeutics and diagnostics, increasing venture capitalist and governmental funding and support, and rapid technological innovations are other factors driving this market's growth. The relatively-untapped Asia-Pacificmarket,and the growth in magnitude of R&D activities in the region,has opened an array of opportunities for players in the oligonucleotide synthesis market. However, regulatory barriers, especially for therapeutic oligos, and downward pricing pressure are the major factors restraining the growth of this market. By products and services, the market is broadly segmented into equipment, reagents, and synthesized oligonucleotides. Among these segments, the synthesized oligonucleotides market segment is expected to register the highest growth rate during the forecast period, owing to the increasing number of applications of synthesized oligonucleotides in research, diagnostics and therapeutics, and a growing demand for custom oligos. The market, by applications, is classified into diagnostics, research, and therapeutics. Research applications are further segmented into PCR, qPCR, sequencing, gene synthesis, and others. The therapeutics market is further segmented into DNA/antisense oligos, RNAi, aptamers, and others. In terms of applications, the research segment commanded the largest share in 2014, while the diagnostics segment is expected to be the fastest-growing segment in the oligonucleotide synthesis market. The therapeutics segment is gaining increasing importance with growing RNAi applications. However, stringent regulatory requirements pose a major challenge for this market. By end users, the market is segmented into academic research institutes, pharmaceutical and biotech firms, and diagnostic labs. Academic research institutes accounted for the largest share of the market in 2014; however, diagnostic laboratories are expected to be the fastest-growing end user segment during the forecast period, owing to growthin the molecular diagnostics field. Scope of the Report By Products & Services - Equipment - Reagents - Synthesized Oligonucleotides By Product Type - Primers - Probes - Intermediate-Scale Synthesis - Large-Scale Synthesis By Service Type - Pre-designed Oligos - Custom Oligos By Application Diagnostics Research - PCR - QPCR - Sequencing - Gene Synthesis - Others Therapeutics - DNA/Antisense Oligos - RNAi Oligos - Aptamer Oligos - Others By End User - Academic Research Institutes - Diagnostic Laboratories - Pharmaceutical & Biotechnology Companies - Others Companies Mentioned - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/c3...nucleotide
Market Maker Surveillance Report. BAC, GE, MRVL, USB, WFC, GCVRZ, Bullishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. BANK OF AMERICA CORPORATION (NYSE:BAC), General Electric Co (NYSE:GE), Marvell Technology Group Ltd (NASDAQ:MRVL), U.S. Bancorp (NYSE:USB), WELLS FARGO & COMPANY (NYSE:WFC), Sanofi SA (NASDAQ:GCVRZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Regulators may put stricter oversight on MetLife
By MARCY GORDON - AP - Thu Sep 04, 6:32PM CDT
WASHINGTON (AP) — U.S. regulators are proposing to label insurer MetLife Inc. as a potential threat to the financial system, a designation that brings stricter government oversight.
GE 3D imaging device OK'd
at Investor's Business Daily - Thu Sep 04, 5:43PM CDT
A 3D breast cancer imaging device developed by General Electric (GE) won FDA approval, the company said. The device is expected to provide a clearer view of carcinomas but produce no more radiation than today's 2D devices. It's also seen increasing...
Final Glance: Tools and Appliances companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top tools and appliances companies were mixed at the close of trading:
GE, Electrolux Deal Could Be Announced Next Week
at Investor's Business Daily - Thu Sep 04, 12:43PM CDT
General Electric (GE) could reach a deal to sell its home appliance business to Electrolux as early as next week, according to a Reuters report Thursday. The conglomerate has been looking to shed underperforming segments to focus on its industrial...
